HealthQuill autoimmune diseases
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Drugs Health Pharma

Novartis to pay Monte Rosa $150m upfront for MGD drug candidates

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.

Read More
Switzerland’s healthcare company, Roche, signed a pact with US-based Alnylam to jointly develop and commercialize a therapy to treat hypertension in people with high cardiovascular risk.
Drugs Health Medical

Molecular coating on X chromosomes may explain higher autoimmune susceptibility in women

Bharti Jayshankar February 2, 2024: A new study has come up with an explanation for the heightened susceptibility of women to autoimmune diseases.

Read More
Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an online statement.
Drugs Health Pharma

Eli Lilly to acquire Dice Therapeutics by third quarter for $2.4 billion 

HQ Team June 20, 2023: Eli Lilly and Company will acquire Dice Therapeutics for $2.4 billion to expand its immunology business, according to an.

Read More
The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories, after Yemen and Lebanon raised concerns.
Drugs Medical Pharma

Yemen, Lebanon allege India’s Celon Labs’ drug ‘substandard’

The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories,.

Read More